In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kevin Grogan

Managing Editor, Europe

Manchester, UK

Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Latest From Kevin Grogan

The New Challenge For The Architect Of Wegovy

Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.

C-Suite Speaks Outlook 2024

Europe’s Biotech Sector Still In Reasonable Shape

Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.

Financing C-Suite Speaks

Sosei Heptares Eyes $3bn Sales From IBD Drug Returned By GSK

The first-in-class, oral GPR35 agonist has shown preclinical promise as a potential treatment for gastrointestinal indications such as ulcerative colitis.

Gastrointestinal Deals

Disappointed InDex CONCLUDEs Development Of Ulcerative Colitis Drug

The Swedish biotech's hopes of advancing cobitolimod lie in tatters after a Phase III study of the TLR9 agonist proved futile.

Gastrointestinal Clinical Trials

MorphoSys Keeps The Faith Despite Mixed Data For Myelofibrosis Combo

The jury is out on whether regulators have seen enough to approve pelabresib.

Cancer Clinical Trials

Vision Failure Means End Of The Road For Oxurion

Disappointing data from a trial of the last remaining drug in its pipeline means that the Belgium group formerly known as ThromboGenics is closing its doors after more than 30 years.

Business Strategies Ophthalmic
See All
UsernamePublicRestriction

Register